NewsResearch
FDA Approval: Axicabtagene ciloleucel (Yescarta) for Lymphoma
FDA approved Axicabtagene ciloleucel (Yescarta), a CD19 CAR T-cell therapy, for certain people with lymphoma. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A treatment made from the patient
Axicabtagene ciloleucel, sold as Yescarta, was approved by the FDA in 2017. Its label carries an Initial U.S. Approval date of 2017. It is a CAR T-cell therapy for large B-cell lymphoma.
CAR T-cell therapy is not a drug in the usual sense. NCI calls it a living drug, because it is made from the patient's own T cells. T cells are the immune system's main killers of infected and diseased cells.
The process starts with collecting blood and separating out the T cells. Those cells go to the maker's laboratory. There they are engineered to make new proteins on their surface. Those proteins are chimeric antigen receptors, or CARs. A CAR lets the cell latch onto a marker on a cancer cell. It also boosts the cell's ability to kill. The cells are then grown until there are hundreds of millions of them. That product is shipped back to the hospital and given as a single infusion.
NCI puts the timeline at about 3 to 5 weeks from blood collection to infusion.
What it is approved for
The FDA's listing for Yescarta names three groups of adults.
The first is large B-cell lymphoma that is refractory to first-line chemoimmunotherapy, or that relapses within 12 months of it. Refractory means it did not respond.
The second is relapsed or refractory large B-cell lymphoma after two or more lines of therapy. That group covers several subtypes. It includes diffuse large B-cell lymphoma, or DLBCL, not otherwise specified. It also includes primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma. And it includes DLBCL that grew out of follicular lymphoma.
The third is relapsed or refractory follicular lymphoma after two or more lines of therapy. The FDA notes that this last use was granted under accelerated approval, based on response rate. Continued approval may depend on confirmatory trials.
NCI adds that the therapy is available only through a special program called Yescarta REMS, short for Risk Evaluation and Mitigation Strategies.
The risks that define the treatment
The label carries a boxed warning, the FDA's most serious warning format. It names three problems.
Cytokine release syndrome, or CRS. When the new cells switch on, they release a flood of immune signals. The label states that CRS has occurred, including fatal or life-threatening cases. It says not to give the therapy to patients with active infection or inflammatory disorders. It says to treat severe CRS with tocilizumab, or with tocilizumab plus steroids.
Neurologic toxicities. These have also included fatal or life-threatening reactions. They can occur alongside CRS or after CRS has resolved, so monitoring continues after the immediate reaction passes.
Secondary blood cancers. The label states that T cell cancers have occurred after this class of therapy. That applies to CD19-directed and BCMA-directed engineered T cell products, including this one.
This is why the therapy is given at certified centers, with close watching for weeks afterward.
When to get checked
NCI lists these signs and symptoms of non-Hodgkin lymphoma. Check with a doctor for:
- Swelling of lymph nodes in the neck, underarm, groin, or stomach.
- Fever for no known reason.
- Drenching night sweats.
- Feeling very tired.
- Weight loss for no known reason.
- Skin rash or itchy skin.
- Pain in the chest, abdomen, or bones for no known reason.
When fever, drenching night sweats, and weight loss occur together, that trio has a name. Clinicians call them B symptoms, and they carry weight in staging and in treatment decisions.
Other symptoms depend on where the cancer forms, how big the tumor is, and how fast it grows. There is no screening program for lymphoma in people without symptoms.
Getting to a subtype
Tests of the lymph system and other parts of the body diagnose and stage non-Hodgkin lymphoma. A complete blood count checks red cells, white cells, and platelets. The diagnosis itself needs tissue, so a lymph node is biopsied and examined.
NHL is not one disease. It is a family, and the subtype drives everything. Diffuse large B-cell lymphoma is fast-growing. Follicular lymphoma is indolent, which means slow-growing. NCI notes it may even go away without treatment. It can also change into a faster type, such as DLBCL.
Where cell therapy sits in the sequence
NCI lists the standard types used across non-Hodgkin lymphoma: radiation therapy, chemotherapy, immunotherapy, targeted therapy, plasmapheresis, watchful waiting, antibiotic therapy, surgery, and stem cell transplant.
NCI also states that treatment should be planned by a team of providers who are experts in lymphoma. Subtype, stage, growth rate, and prior treatments all shape the plan. Our page on immunotherapy covers the class this therapy belongs to. Our page on lymphoma covers the disease family.
CAR T-cell therapy sits late in that sequence for most people, after chemoimmunotherapy has failed or the disease has come back quickly.
Numbers for a family of diseases
These SEER figures cover all non-Hodgkin lymphoma, a family that includes both slow and aggressive subtypes. They describe a population, not a person, and they do not describe the group treated with CAR T-cell therapy.
Five-year relative survival for non-Hodgkin lymphoma is 74.3 percent for cases from 2016 to 2022. An estimated 79,320 new cases and 19,970 deaths are projected for 2026. Median age at diagnosis is 68.
SEER reports these cases by Ann Arbor-style stage rather than the localized-to-distant grouping used for solid tumors, because lymphoma staging works differently.
What this does not mean
An approval based on response rate does not prove longer life. The follicular lymphoma indication remains conditional for that reason.
This therapy also has practical limits that a headline rarely mentions. It needs a certified center. It needs a manufacturing window of several weeks. And it needs a patient well enough to wait through that. Whether it fits one person depends on subtype, prior treatments, organ function, and access to close monitoring.
Sources
- FDA, YESCARTA (axicabtagene ciloleucel) product page — https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel
- NCI, Axicabtagene Ciloleucel — https://www.cancer.gov/about-cancer/treatment/drugs/axicabtageneciloleucel
- DailyMed, YESCARTA (axicabtagene ciloleucel) label, Initial U.S. Approval 2017 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59
- NCI, CAR T Cells: Engineering Immune Cells to Treat Cancer — https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
- NCI PDQ, Adult Non-Hodgkin Lymphoma Treatment (Patient Version) — https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
- SEER Cancer Stat Facts, Non-Hodgkin Lymphoma — https://seer.cancer.gov/statfacts/html/nhl.html
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Lymphoma. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.